Par Pharmaceutical, Inc. Recalls Mycophenolate Mofetil for Injection, USP
The company is recalling one lot of Mycophenolate Mofetil for Injection, USP because of glass fragments found in a vial after reconstitution.
Endo International plc announced on May 1, 2019 that one of its operating companies, Par Pharmaceutical, Inc., is voluntarily recalling one lot of Mycophenolate Mofetil for Injection, USP. The recall was initiated after a glass fragment was found in one vial of product after reconstitution.
The recalled lot, AD812, expiry 09/2020, was manufactured for Par Pharmaceutical, Inc. by Gland Pharma Limited and distributed nationwide to wholesale distribution locations between Jan. 23 and Feb. 11, 2019. Mycophenolate Mofetil for Injection, USP is packaged in cartons of four single use vials with NDC 42023-172-04.
While the company has not received any reports of adverse events, it warns that administration of a glass particulate in an intravenous drug may result in local irritation, swelling, or more seriously, blockage and clotting in blood vessels. Adverse events may be reported to FDA via its MedWatch program.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
